Cargando…

Development of an anti-ferret CD4 monoclonal antibody for the characterisation of ferret T lymphocytes

The ferret is an established animal model for a number of human respiratory viral infections, such as influenza virus and more recently, Ebola virus. However, a paucity of immunological reagents has hampered the study of cellular immune responses. Here we describe the development and characterisatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Layton, Daniel S., Xiao, Xiaowen, Bentley, John D., Lu, Louis, Stewart, Cameron R., Bean, Andrew G.D., Adams, Timothy E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094458/
https://www.ncbi.nlm.nih.gov/pubmed/28216237
http://dx.doi.org/10.1016/j.jim.2017.02.009
_version_ 1783510474844798976
author Layton, Daniel S.
Xiao, Xiaowen
Bentley, John D.
Lu, Louis
Stewart, Cameron R.
Bean, Andrew G.D.
Adams, Timothy E.
author_facet Layton, Daniel S.
Xiao, Xiaowen
Bentley, John D.
Lu, Louis
Stewart, Cameron R.
Bean, Andrew G.D.
Adams, Timothy E.
author_sort Layton, Daniel S.
collection PubMed
description The ferret is an established animal model for a number of human respiratory viral infections, such as influenza virus and more recently, Ebola virus. However, a paucity of immunological reagents has hampered the study of cellular immune responses. Here we describe the development and characterisation of a novel monoclonal antibody (mAb) against the ferret CD4 antigen and the characterisation of ferret CD4 T lymphocytes. Recombinant production and purification of the ferret CD4 ectodomain soluble protein allowed hybridoma generation and the generation of a mAb (FeCD4) showing strong binding to ferret CD4 protein and lymphoid cells by flow cytometry. FeCD4 bound to its cognate antigen post-fixation with paraformaldehyde (PFA) which is routinely used to inactivate highly pathogenic viruses. We have also used FeCD4 in conjunction with other immune cell markers to characterise ferret T cells in both primary and secondary lymphoid organs. In summary, we have developed an important reagent for the study of cellular immunological responses in the ferret model of infectious disease.
format Online
Article
Text
id pubmed-7094458
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-70944582020-03-25 Development of an anti-ferret CD4 monoclonal antibody for the characterisation of ferret T lymphocytes Layton, Daniel S. Xiao, Xiaowen Bentley, John D. Lu, Louis Stewart, Cameron R. Bean, Andrew G.D. Adams, Timothy E. J Immunol Methods Article The ferret is an established animal model for a number of human respiratory viral infections, such as influenza virus and more recently, Ebola virus. However, a paucity of immunological reagents has hampered the study of cellular immune responses. Here we describe the development and characterisation of a novel monoclonal antibody (mAb) against the ferret CD4 antigen and the characterisation of ferret CD4 T lymphocytes. Recombinant production and purification of the ferret CD4 ectodomain soluble protein allowed hybridoma generation and the generation of a mAb (FeCD4) showing strong binding to ferret CD4 protein and lymphoid cells by flow cytometry. FeCD4 bound to its cognate antigen post-fixation with paraformaldehyde (PFA) which is routinely used to inactivate highly pathogenic viruses. We have also used FeCD4 in conjunction with other immune cell markers to characterise ferret T cells in both primary and secondary lymphoid organs. In summary, we have developed an important reagent for the study of cellular immunological responses in the ferret model of infectious disease. Elsevier B.V. 2017-05 2017-02-16 /pmc/articles/PMC7094458/ /pubmed/28216237 http://dx.doi.org/10.1016/j.jim.2017.02.009 Text en © 2017 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Layton, Daniel S.
Xiao, Xiaowen
Bentley, John D.
Lu, Louis
Stewart, Cameron R.
Bean, Andrew G.D.
Adams, Timothy E.
Development of an anti-ferret CD4 monoclonal antibody for the characterisation of ferret T lymphocytes
title Development of an anti-ferret CD4 monoclonal antibody for the characterisation of ferret T lymphocytes
title_full Development of an anti-ferret CD4 monoclonal antibody for the characterisation of ferret T lymphocytes
title_fullStr Development of an anti-ferret CD4 monoclonal antibody for the characterisation of ferret T lymphocytes
title_full_unstemmed Development of an anti-ferret CD4 monoclonal antibody for the characterisation of ferret T lymphocytes
title_short Development of an anti-ferret CD4 monoclonal antibody for the characterisation of ferret T lymphocytes
title_sort development of an anti-ferret cd4 monoclonal antibody for the characterisation of ferret t lymphocytes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094458/
https://www.ncbi.nlm.nih.gov/pubmed/28216237
http://dx.doi.org/10.1016/j.jim.2017.02.009
work_keys_str_mv AT laytondaniels developmentofanantiferretcd4monoclonalantibodyforthecharacterisationofferrettlymphocytes
AT xiaoxiaowen developmentofanantiferretcd4monoclonalantibodyforthecharacterisationofferrettlymphocytes
AT bentleyjohnd developmentofanantiferretcd4monoclonalantibodyforthecharacterisationofferrettlymphocytes
AT lulouis developmentofanantiferretcd4monoclonalantibodyforthecharacterisationofferrettlymphocytes
AT stewartcameronr developmentofanantiferretcd4monoclonalantibodyforthecharacterisationofferrettlymphocytes
AT beanandrewgd developmentofanantiferretcd4monoclonalantibodyforthecharacterisationofferrettlymphocytes
AT adamstimothye developmentofanantiferretcd4monoclonalantibodyforthecharacterisationofferrettlymphocytes